1. Scrip
  2. >>Leadership
  3. >>Executives On The Move

Appointments: Neurotrope, Concert, Lannett, Peregrine, Allergan, Amneal, Acticor, Alliance Pharma

 
• By Scrip Team

The latest biopharma industry appointments include new CEOs at Neurotrope, Lannett, Amneal and Peregrine Pharmaceuticals, a new CFO at Concert Pharmaceuticals, a new EVP of global operations at Allergan, a new CMO at Acticor, and a US country manager for Alliance Pharma.

Neurotrope Inc. has appointed Charles Ryan CEO, effective Feb. 15, 2018, following the resignation of Susanne Wilke. Ryan served as senior vice president and chief intellectual property counsel at Forest Laboratories for more than 10 years, and is currently president and CEO of Orthobond Corp. Neurotrope is evaluating bryostatin-1 in a Phase II study for advanced Alzheimer's disease, and is conducting preclinical studies of bryostatin for Fragile X syndrome, Niemann-Pick type C disease, and Rett syndrome.

Concert Pharmaceuticals Inc., the US biopharma company creating a pipeline of deuterated new medicines, has appointed Marc Becker as CFO, effective Jan. 4, 2018

More from Executives On The Move

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.

Executives On The Move: Six CMOs, Five CEOs And Two CSOs Among This Week’s Changes

Recent moves in the industry include C-suite changes at Merck KGaA, Newleos Therapeutics and Artiva Biotherapeutics, plus Valo Therapeutics acquires chief executive officer from Johnson & Johnson.

More from Leadership

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.